CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine.
To reduce the biothreat posed by anthrax, efforts are under way to improve the protection afforded by vaccination. This work examines the ability of immunostimulatory CpG oligodeoxynucleotides (ODN) adsorbed onto cationic polylactide-co-glycolide (PLG) microparticles (CpG ODN-PLG) to accelerate and boost the protective immunity elicited by Anthrax Vaccine Adsorbed (AVA, the licensed human anthrax vaccine). The results indicate that coadministering CpG ODN-PLG with AVA induces a stronger and faster immunoglobulin G response against the protective antigen of anthrax than AVA alone. Immunized mice were protected from lethal anthrax challenge within 1 week of vaccination with CpG ODN-PLG plus AVA, with the level of protection correlating with serum immunoglobulin G anti-protective antigen titers.
Xie
Hang
H
Center for Biologics Evaluation Research, Food and Drug Administration, Bldg. 29A, Rm. 3D10, Bethesda, MD 20892, USA.
Gursel
Ihsan
I
Ivins
Bruce E
BE
Singh
Manmohan
M
O'Hagan
Derek T
DT
Ulmer
Jeffrey B
JB
Klinman
Dennis M
DM
D000818:Animals; D000881:Anthrax / Q000276:immunology / Q000517:prevention & control; D022122:Anthrax Vaccines / Q000276:immunology*; D008297:Male; D051379:Mice; D008863:Microspheres; D009838:Oligodeoxyribonucleotides / Q000276:immunology*; D011098:Polyglactin 910; D013997:Time Factors
D022122:Anthrax Vaccines; D009838:Oligodeoxyribonucleotides; D011098:Polyglactin 910